Targeted Oncology
Targeted Oncology
Targeted Oncology
Optune TM Logo

Alternating Electric Field Therapy (Optune)
Is Part of a National Comprehensive
Cancer Network® (NCCN®) Category 2A Recommended Treatment Option1

Novocure™ is pleased to announce that the updated NCCN Clinical Practice Guidelines
In Oncology® (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following standard brain radiation therapy with concurrent TMZ as a Category 2A recommended postoperative adjuvant treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM).1
a Alternating electric field therapy is only an option for patients with supratentorial disease. b Combination of agents may lead to increased toxicity or radiographic changes. cBenefit of treatment with TMZ for GBM beyond 6 months is unknown. d Clinical benefit from TMZ is likely to be lower in patients whose tumors lack MGMT promoter methylation.
Note: All recommendations are category 2A unless otherwise indicated.
KPS, Karnofsky Performance Status; MGMT, O6-methylguanine-DNA methytransferase; RT, radiation therapy.
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers.?V.1.2016.??2016 National Comprehensive Cancer Network, Inc.?All rights reserved.?Accessed July 25, 2016. The NCCN Guidelines®?and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN.?To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.?NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
Optune + TMZ?a standard treatment option for newly diagnosed GBM. Learn more
Indication For Use2
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.
Important Safety Information
Contraindications
Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.
Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.
Warnings and Precautions
Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).
Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.
The most common (≤10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.
Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.
If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.
Please see the Optune Instructions For Use (IFU) for complete information regarding the device's indication, contraindications, warnings, and precautions at Optune.com/IFU.
With appreciation,
Pritesh Shah
US General Manager
To learn more about Optune, visit Optune.com
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers.?V.1.2016. ?2016 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed July 25, 2016. The NCCN Guidelines®?and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN.?To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.?NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. Optune Instructions For Use. Novocure 2016.
Facebook icon Youtube icon
Novocure TM Logo ©2016 Novocure. All rights reserved. Optune and Novocure are trademarks of Novocure. OPT-428